126 research outputs found
Complement in Metastasis: A Comp in the Camp
The complement system represents a pillar of the innate immune response. This system, critical for host defense against pathogens, encompasses more than 50 soluble, and membrane-bound proteins. Emerging evidence underscores its clinical relevance in tumor progression and its role in metastasis, one of the hallmarks of cancer. The multistep process of metastasis entails the acquisition of advantageous functions required for the formation of secondary tumors. Thus, targeting components of the complement system could impact not only on tumor initiation but also on several crucial steps along tumor dissemination. This novel vulnerability could be concomitantly exploited with current strategies overcoming tumor-mediated immunosuppression to provide a substantial clinical benefit in the treatment of metastatic disease. In this review, we offer a tour d'horizon on recent advances in this area and their prospective potential for cancer treatment
Hamilton-Jacobi theory and the evolution operator
We present a new setting of the geometric Hamilton-Jacobi theory by using the so-called time-evolution operator K. This new approach unifies both the Lagrangian and
the Hamiltonian formulation of the problem developed in [7], and can be applied to the
case of singular Lagrangian dynamical systems.Postprint (published version
Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway
The molecular hallmarks of inflammation-mediated lung carcinogenesis have not been fully clarified, mainly due to the scarcity of appropriate animal models. We have used a silica-induced multistep lung carcinogenesis model driven by chronic inflammation to study the evolution of molecular markers and genetic alterations. We analyzed markers of DNA damage response (DDR), proliferative stress, and telomeric stress: gamma-H2AX, p16, p53, and TERT. Lung cancer-related epigenetic and genetic alterations, including promoter hypermethylation status of p16(CDKN2A), APC, CDH13, Rassf1, and Nore1A, as well as mutations of Tp53, epidermal growth factor receptor, K-ras, N-ras, and c-H-ras, have been also studied. Our results showed DDR pathway activation in preneoplastic lesions, in association with inducible nitric oxide synthase and p53 induction. p16 was also induced in early tumorigenic progression and was inactivated in bronchiolar dysplasias and tumors. Remarkably, lack of mutations of Ras and epidermal growth factor receptor, and a very low frequency of Tp53 mutations suggest that they are not required for tumorigenesis in this model. In contrast, epigenetic alterations in p16(CDKN2A), CDH13, and APC, but not in Rassf1 and Nore1A, were clearly observed. These data suggest the existence of a specific molecular signature of inflammation-driven lung carcinogenesis that shares some, but not all, of the molecular landmarks of chemically induced lung cancer
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative therapeutic strategies. Here we report the identification of a common transcriptional signature across mutant KRAS cancers of distinct tissue origin that includes the transcription factor FOSL1. High FOSL1 expression identifies mutant KRAS lung and pancreatic cancer patients with the worst survival outcome. Furthermore, FOSL1 genetic inhibition is detrimental to both KRAS-driven tumour types. Mechanistically, FOSL1 links the KRAS oncogene to components of the mitotic machinery, a pathway previously postulated to function orthogonally to oncogenic KRAS. FOSL1 targets include AURKA, whose inhibition impairs viability of mutant KRAS cells. Lastly, combination of AURKA and MEK inhibitors induces a deleterious effect on mutant KRAS cells. Our findings unveil KRAS downstream effectors that provide opportunities to treat KRAS-driven cancers
Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis
Loss of the epithelial phenotype and disruption of adhesion molecules is a hallmark in the epithelial-mesenchymal transition (EMT) reported in several types of cancer. Most of the studies about the relevance of adhesion and junction molecules in lung cancer have been performed using established tumors or in vitro models. The sequential molecular events leading to EMT during lung cancer progression are still not well understood. We have used a rat model for multistep lung carcinogenesis to study the status of adherens and tight junction proteins and mesenchymal markers during EMT. After silica-induced chronic inflammation, rats sequentially develop epithelial hyperplasia, preneoplastic lesions, and tumors such as adenocarcinomas and squamous cell carcinomas. In comparison with normal and hyperplastic bronchiolar epithelium and with hyperplastic alveolar type II cells, the expression levels of E-cadherin, alpha-catenin and beta-catenin were significantly reduced in adenomatoid preneoplastic lesions and in late tumors. The loss of E-cadherin in tumors was associated with its promoter hypermethylation. alpha- and beta-catenin dysregulation lead to cytoplasmic accumulation in some carcinomas. No nuclear beta-catenin localization was found at any stage of any preneoplastic or neoplastic lesion. Zonula occludens protein-1 was markedly decreased in 66% of adenocarcinomas and in 100% squamous cell carcinomas. The mesenchymal-associated proteins N-cadherin and vimentin were analyzed as markers for EMT. N-cadherin was de novo expressed in 32% of adenocarcinomas and 33% of squamous cell carcinomas. Vimentin-positive tumor cells were found in 35% of adenocarcinomas and 88% of squamous cell carcinomas. Mesenchymal markers were absent in precursor lesions, both hyperplastic and adenomatoid. The present results show that silica-induced rat lung carcinogenesis is a good model to study EMT in vivo, and also provide in vivo evidence suggesting that the changes in cell-cell adhesion molecules are an early event in lung carcinogenesis, while EMT occurs at a later stage
Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis
Osteosarcoma is the most prevalent bone tumor in children and
adolescents. At present, the mechanisms of initiation, maintenance, and
metastasis are poorly understood. The purpose of this study was to identify
relevant molecular targets in the pathogenesis of osteosarcoma. EXPERIMENTAL
DESIGN: Tumor chemonaive osteoblastic populations and paired control normal
osteoblasts were isolated and characterized phenotypically from seven
osteosarcoma patients. Global transcriptomic profiling was analyzed by robust
microarray analysis. Candidate genes were confirmed by real-time PCR and
organized in molecular pathways. EBF2 and osteoprotegerin (OPG) levels were
determined by real-time PCR and OPG protein levels were assessed by ELISA.
Immunohistochemical analysis was done in a panel of 46 osteosarcoma samples.
Silencing of EBF2 was achieved by lentiviral transduction of short hairpin RNA.
Apoptosis was determined by caspase-3/7 activity. RESULTS: A robust clustered
transcriptomic signature was obtained in osteosarcoma. Transcription factor EBF2,
a known functional bone regulator, was among the most significantly overexpressed
genes. Immunohistochemical analysis showed that osteosarcoma is expressed in
approximately 70% of tumors analyzed. Because EBF2 was shown previously to act as
a transcriptional activator of OPG, elevated levels of EBF2 were associated with
high OPG protein levels in osteosarcoma samples compared with normal osteoblastic
cells. Knockdown of EBF2 led to stunted abrogation of OPG levels and increased
sensitivity to tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis. CONCLUSIONS: These findings suggest that EBF2
represents a novel marker of osteosarcoma. EBF2 up-regulation may be one of the
mechanisms involved in the high levels of OPG in osteosarcoma, contributing to
decrease TRAIL-induced apoptosis and leading to TRAIL resistance
CDH11 Expression is Associated with Survival in Patients with Osteosarcoma
Previous studies have shown that cadherin-11 (CDH11) may be involved in the
metastatic process of osteosarcoma. The correlation of the expression levels of
CDH11 in osteosarcoma samples with the risk of disease progression and metastasis
was examined. Real time qRT-PCR was used to quantify CDH11 expression in a set of
newly established osteosarcoma cell lines, 11 primaries and five metastases,
compared to the levels in 12 normal osteoblast cell lines established from
healthy bone, and also in a set of 10 snap-frozen osteosarcoma samples. In all
cases long term clinical follow-up data was available. The CDH11 expression level
decreased gradually from the osteoblast to the primary cell lines (p=0.2184) and
further to those established from the tumor metastases (p=0.0275). Importantly,
the level of CDH11 expression correlated significantly (p=0.01) with patient
survival (Kaplan-Meier survival analysis) in both sample sets (p=0.0128 for the
cell lines, p=0.0492 for the biopsies). In conclusion, the results indicate that
CDH11 may be useful as a prognostic marker of disease progression and survival in
osteosarcoma
Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival
The cortactin (CTTN) gene has been found, by transcriptomic
profiling, to be overexpressed in pediatric osteosarcoma. The location of CTTN at
11q13 and the role of cortactin in cytoskeleton restructuring make CTTN of
interest as a potential biomarker for osteosarcoma. MATERIALS AND METHODS:
Osteoblasts were isolated from 20 high-grade osteosarcomas before chemotherapy,
and paired with cell samples from normal tissue, prior to RNA expression analysis
on HG-U133A chips (Affymetrix). Semiquantitative CTTN mRNA expression was
analyzed by real-time PCR. An osteosarcoma tissue microarray (TMA) containing 233
tissue spots from 48 patients was used for an immunohistochemical (IHC) study of
cortactin. RESULTS: Transcriptomic profiling and real-time PCR analysis indicated
increased CTTN expression in osteosarcomas (p = 0.001, Student's T test). TMA IHC
showed cortactin to be present more frequently and in greater abundance in
osteosarcomas than non-tumoral osteoblastic samples (p< 0.006, Mann-Withney
test). Analysis of clinical outcomes indicated that overall survival for patients
with primary tumors positive for cortactin was significantly lower than that for
patients with cortactin negative (or only weakly staining) tumors (p = 0.0278,
Log-rank test). CONCLUSIONS: Our preliminary data support the hypothesis that
over-expression of cortactin, contained in the 11q13 amplicon, is involved in
osteosarcoma carcinogenesis. The potential of cortactin overexpression as a
biomarker for osteosarcoma is consolidated
- …